WuXi Biologics Reports Solid 2024 Annual Results and Expects Accelerated Growth in 2025 Revenue grew 9.6% YoY to RMB 18,675.4 million, with ...
Aragen, a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced two senior level appointments. Dr. Manjunath Rama...
Key Financial Highlights: Full-year net sales increased to €21.2 billion (organically: +2.0%) EBITDA pre rose to €6.1 billion (orga...
Fourth Quarter 2024 Total Revenues of $194.7 million; Full Year 2024 Total Revenues of $1.04 billion Fourth Quarter 2024 Net Loss of $31.3 million, de...
Appointment of three internal senior executives ensures strategic continuity with a new era of leadership Jean-Charles Wirth to become CEO Life Scienc...
Artificial intelligence is reshaping oncology, and ImpriMed is at the forefront of this transformation. With its AI-powered Personalized Prediction Profi...
AstraZeneca delivered $54.1 billion in total revenue for FY 2024, a 21% increase at constant exchange rates (CER), fueled by strong growth across oncolog...
Illumina, led by CEO Jacob Thaysen, delivered a Q4 revenue of $1.1 billion, reflecting a steady 1% year-over-year increase, w...
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced its financial results for the first quarter ...
Fourth-Quarter Worldwide Sales Were $15.6 Billion, an Increase of 7% From Fourth Quarter 2023; Excluding the Impact of Foreign Exchange, Growth W...
Pfizer Inc. reported robust financial results for the full year 2024, achieving total revenues of $63.6 billion, reflecting a 7% year-over-year operation...
Net sales grew +12% (cc1, +11% USD) with core operating income1 up +22% (cc, +19% USD) Sales growth driven by continued strong performance from Ent...
In 2024, Lonza delivered sales of CHF 6.6 billion in line with prior year (-0.2% CER1) CORE EBITDA of CHF 1.9 billion at a margin of 29.0% The CDMO...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year...
© 2025 Biopharma Boardroom. All Rights Reserved.
